The Biotechnology Business Institute closes the 5th edition of the Scientific MBA in Lifesciences with a great success and four projects developing drug candidates.


Jul 3, 2019


Four drug candidates targeting three indications, Breast Cancer, Chron’s Syndrome and NASH (nonalcoholic steatohepatitis), were presented by our students in the closing ceremony of the Scientific MBA's as a result of a year developing different intellectual properties for potential new treatments

This academic year 2018-2019, our students started the master programs with four different patents that protected potential compounds to become new treatments, two new small entities, one cell therapy and one small peptide. The target indication selected by our students for these projects after meeting with the principal researchers and the technology transfer office managers were breast cancer triple negative and luminal, the most aggressive type of breast cancer, Chron’s disease, with a new approach of the overall current therapies, and Nash (nonalcoholic steatohepatitis) due to the metabolic effects of one of them and the absence of actual treatment. 

The thesis jury was composed by Andrea Sáez, Investment analyst at Asabys Partners, Maribel Berges, Entrepreneur in lifesciences and Juan R. Garcia, board Chairman at the Biotechnology Business Institute. The objective these presentations is to stablish the scientific and regulatory paths, preclinical and clinical, to develop these indications through the FDA and EMA further to launch approval and market access as well as developing the business model were the investments need and the, the valuation of the IP and the exit strategy for the return of the investment is established.

Once again, the master students defended those conclusions showing, on one hand the potential of our institutions to continue development early stage science and how scientific managers are key in those processes.

The Biotechnology Business Institute Direction thanks our innovation managers, Coordinators, Board of Professors and Jury for another excellent year of hard work and congratulations to all of our students for the excellent results obtained and the effort during the academic year.

We look forward to the next edition.

Learn more about Discover & Transfer

 

Learn more about Scientific MBAs

 

Press Release

Latest news

The Biotechnology Business Institute closes the 5th edition of the Scientific MBA in Lifesciences with a great success and four projects developing drug candidates.

Four drug candidates targeting three indications, Breast Cancer, Chron’s Syndrome and NASH (nonalcoholic steatohepatitis), were presented by our students in the closing ceremony of the Scientific MBA’s as a result of a year developing different intellectual properties for potential new treatments

BBI Case Study in International Strategy. Aortyx, a success case in early stage funding for medical device focus in aortic disease

During the evening of the BBI Open Day a study case in early stage funding was presented by Jordi Martorell, Patrick O’Brien, Lifesciences consultant, and William Hariri, Director at Alira Health. The main objective of the evening was to understand how to develop and international strategy for medical devices.

The Biotechnology Business Institute closes the first BBI Open Day with great success inspiring young scientific professionals

The importance of scientific profiles in a society based in innovation and how their professional development in management can contribute to drug discovery, were some of the main topics presented during the BBI Open Day 2019

The first 2019 BioInternational Seminar is a success and gain interest between scientific profiles with vision in drug discovery

International experts shared their experience and knowledge in the pharmaceutical industry and the biotechnology sector over an evening with young scientific profiles developing their career in the drug discovery field

Filter by category